Scancell Holdings Plc (SCLP) - Hardman Res. - Validating multiple opportunities
16 February 2018 - 12:17AM
ADVFN NewsWire
Hardman Research -
Validating multiple opportunities
Validating and de-risking of multiple
opportunities: Scancell is a clinical-stage
biotechnology company developing two distinct flexible cancer
immunotherapy platforms, each with broad applications: ImmunoBody
is a DNA vaccine that stimulates high-avidity anti-tumour CD8+
T-cells for use as a monotherapy or in combination with checkpoint
inhibitors (CPIs); Moditope targets modified antigens and
stimulates powerful anti-tumour CD4+ T-cell responses for use in
advanced and hard-to-treat cancers. Both technologies have been
externally validated recently through partnership deals with Cancer
Research UK (CRUK; ImmunoBody SCIB2) and BioNTech (Moditope),
providing significant endorsements.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/scancell-documents/15.02.18-validating-and-de-risking-of-multiple-opportunities.pdf
About Hardman & Co: For the past 21 years
Hardman has been producing specialist research designed to improve
investors' understanding of companies, sectors, industries and
investment securities. Our analysts are highly experienced in their
sectors, and have often been highly rated by professional investors
for their knowledge. Our focus is to raise companies' profiles
across the UK and abroad with outstanding research, investor
engagement programmes and advisory services. Some of our notes have
been commissioned by the company which is the subject of the note;
this is clearly stated in the disclaimer where this is the
case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024